Navigation Links
New Hope for Treatment of Pancreatic Cancer
Date:9/25/2009

By inhibiting key enzyme, researchers shrank tumors, prolonged survival in mice

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: European Cancer Organization, news release, Sept. 24, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Treatment May Beat Melanoma
2. Lifestyle interventions in the prevention and treatment of cancer
3. M. D. Anderson examines use of toad venom in cancer treatment
4. Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors From Promise to Reality As Parkinsons Treatment
5. Shady Grove Fertility Center Presents 5K Fundraising Race to Help Families Afford Fertility Treatment or Adoption
6. Study reveals 2/3 of prostate cancer patients do not need treatment
7. Discovery could improve hepatitis C treatment
8. Targeted heat therapy offers new standard treatment option for soft tissue sarcoma
9. National Autism Center Releases Groundbreaking Report on Autism Treatments
10. Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments
11. FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytrens Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Hope for Treatment of Pancreatic Cancer
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... which is has been collaborating with doctors and hospitals to make transformative changes ... the world’s leading cell therapy minds this week in discussing breakthroughs in cellular ...
(Date:4/28/2016)... ... ... Medical Card reminds us that May is National Stroke Awareness Month. According to the ... death in the United States; someone has one every 40 seconds. Annually, almost 800,000 ... years old. A stroke is when blood flow to the brain is blocked or ...
(Date:4/28/2016)... ... 28, 2016 , ... April, 28, 2016 – Magee Rehabilitation ... Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s annual Top Doctors list ... and medical leadership across the country. These select individuals nominate outstanding physicians in ...
(Date:4/28/2016)... ... , ... Denise McCormick Baich had written poetry dating back to her childhood, but after several ... tsunami and took on a more spiritual tone. The desire to put the words on ... it than just file it away. Friends would ask her how she wrote such wonderful ...
(Date:4/28/2016)... ... April 28, 2016 , ... Prescription ... co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy program. ... medications from over 180 American pharmaceutical companies for $35 per month, per ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... a developer of a new generation of drugs ... overall survival results for Paclical/Apealea in the Phase ... patients with epithelial ovarian cancer. These preliminary results ... in combination with carboplatin versus Taxol in combination ...
(Date:4/26/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased ... Pharm D., to Vice President of Education and Quality. ... will continue to lead and oversee Diplomat University, an ... and training to Diplomat employees and external professionals on ... also houses the quality assurance department, which focuses on ...
(Date:4/26/2016)... -- Research and Markets has announced the addition ... the Biological Medicine Industry in China 2016"  report to ... financial assessment and credit risk of the biological medicine ... provides readers with an in-depth understanding of the industry ... aware of. It considers current and future drivers, challenge ...
Breaking Medicine Technology: